Advances in stem cell therapy for heart regeneration and repair: Current trends and challenges
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The human heart has long been considered a terminally differentiated organ incapable of meaningful self-repair after ischemic injury, but three decades of stem cell research have begun to challenge that assumption. This research evaluated the comparative efficacy of three cell-based regenerative approaches-bone marrow-derived mesenchymal stem cells (BM-MSCs), cardiac progenitor cells (CPCs), and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs)-in patients with chronic heart failure following myocardial infarction. A total of 169 patients were enrolled across two Irish academic medical centers between February 2022 and October 2024, with 47 receiving BM-MSCs, 39 receiving CPCs, 31 receiving iPSC-CMs, and 52 serving as standard-of-care controls. The primary endpoint was change in left ventricular ejection fraction (LVEF) measured by cardiac magnetic resonance imaging at 24 months. Secondary endpoints included infarct size reduction, MACE-free survival, and functional capacity assessed by six-minute walk distance. IPSC-CM recipients demonstrated the greatest LVEF improvement, rising from a baseline of 33.1% to 52.8% at 24 months (mean gain 19.7 percentage points, p
Fields of Study & Subjects
Mesenchymal stem cell research
Congenital heart defects research
Tissue Engineering and Regenerative Medicine
Publication details
- Journal / source
- International Journal of Cardiology Research
- Volume
- 8
- Issue
- 1
- Pages
- 52–58
- Publication date
- 1 January 2026
- Language
- EN